se of Tecovirimat (TPOXX®) for Treatment of Human Non-Variola Orthopoxvirus Infections i
J
John Christenson, MD
Primary Investigator
Overview
The purpose of this expanded access IND (compassionate use) program is to provide stockpiled tecovirimat for treatment of non-variola orthopoxvirus infections and secondary treatment of complications from replication-competent vaccinia vaccine in adults and children.
Description
All patient populations, who meet eligibility criteria, can receive tecovirimat treatment under this IND program (e.g., children and all adults including pregnant and nursing individuals, and prisoners). Clinical considerations of tecovirimat therapy during an outbreak may evolve depending on the duration and nature of the outbreak and event-based information that may become available during the outbreak
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
orthoproxvirus
-
Age: - 100 Years
-
Gender: All
Inclusion Criteria:
Exclusion Criteria:
- Known allergy to tecovirimat and/or inactive ingredients in tecovirimat
- For IV tecovirimat only: patients with severe renal impairment (creatinine clearance <30 mL/min). Oral tecovirimat is an option for patients with severe renal impairment.
Updated on
02 May 2024.
Study ID: 16103; 6402, PINF-CDC-TPOXX-EAP
Please visit our main page to search for other studies you may be interested in.
If you need help finding a study or have any questions, please contact us at inhealth@iu.edu
